Brent J Passer

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models
    B J Passer
    Department of Neurosurgery, Brain Tumor Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Cancer Gene Ther 20:17-24. 2013
  2. ncbi Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells
    B J Passer
    Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Cancer Gene Ther 16:551-60. 2009
  3. ncbi Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures
    B J Passer
    Department of Neurosurgery, Brain Tumor Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Gene Ther 16:1477-82. 2009
  4. ncbi Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication
    Brent J Passer
    Departments of Neurosurgery and Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Cancer Res 70:3890-5. 2010
  5. ncbi Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer
    P Castelo-Branco
    Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Gene Ther 17:805-10. 2010

Collaborators

Detail Information

Publications5

  1. ncbi Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models
    B J Passer
    Department of Neurosurgery, Brain Tumor Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Cancer Gene Ther 20:17-24. 2013
    ..These data highlight the therapeutic advantage of combining the dual-acting antitumor and antiangiogenic activities of oHSVs and MDAs...
  2. ncbi Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells
    B J Passer
    Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Cancer Gene Ther 16:551-60. 2009
    ..These findings suggest that G47Delta may act in part, on mitotically blocked cells to enhance cell death, which may account for the enhanced antitumor efficacy observed in vivo...
  3. ncbi Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures
    B J Passer
    Department of Neurosurgery, Brain Tumor Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Gene Ther 16:1477-82. 2009
    ....
  4. ncbi Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication
    Brent J Passer
    Departments of Neurosurgery and Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Cancer Res 70:3890-5. 2010
    ..Our results indicate that ENT1 antagonists augment oHSV replication in tumor cells by increasing cellular ribonucleoside activity...
  5. ncbi Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer
    P Castelo-Branco
    Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Gene Ther 17:805-10. 2010
    ..These data lend support to the concept of combining oncolytic and immunogenic therapies as a way to improve therapy of metastatic prostate cancer...